BioAdvance News

Niiki Pharma Presents Data on NKP-2235, the First Highly Orally Bioavailable Gallium-Based Anti-Cancer Agent

By WebmasterApril 3, 2012November 1st, 2024No Comments

Niiki Pharma Presents Data on NKP-2235, the First Highly Orally Bioavailable Gallium-Based Anti-Cancer Agent
Read more here

Previous PostFDA Approves Amyvid™ (Florbetapir F 18 Injection) for Use in Patients
Next PostNiiki Pharma to Present Preclinical Results, Start Testing Cancer Drug